Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes

By T. Patterson, W. Kirkpatrick, M. White, J. Hiemenz, J. Wingard, B. Dupont, D. Stevens, J. Graybill. Medicine, 2000

816 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases, Small Animals

View Paper: https://www.semanticscholar.org/paper/33881079f85a9ee01b939ef68cb72da613c4b5ab

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. M. Pfaller
2. D. Diekema
3. T. Walsh
4. J. Perfect
5. J. Guinea

In Infectious Diseases

1. M. Pfaller
2. D. Diekema
3. Henry F. Chambers
4. J. Perfect
5. J. Guinea

In Small Animals

1. M. Pfaller
2. D. Diekema

Citations in the corpus

• Epidemiology of Invasive Mycoses in North America (2010, background): “Nearly two-thirds (61%) of patients with IA have underlying hematological diseases (including hematological malignancies) or have undergone HSCT (Morgan et al. 2005b; Patterson et al. 2000).”
• Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. (2008, neutral): “astating complication of invasive aspergillosis [2, 180, 181].”
• Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007, neutral): “Although there continues to be concern over a perceived increase in both incidence and mortality of IA (43, 44, 51, 85, 132, 149, 154, 194), the overall incidence was almost 10fold lower than that of IC for the years 1996 through 2003 (Table 4).”
• Practice guidelines for the diagnosis and management of skin and soft-tissue infections. (2005, background): “Mortality remains high for all of these infections [188, 190].”
• Voriconazole treatment for less-common, emerging, or refractory fungal infections. (2003, background): “Among all sites of fungal infection, patients with cerebral aspergillosis have the poorest treatment response rate (8%) [31]—and, correspondingly, the highest case fatality rate (88%) [30].”
• Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. (2007, background): “Invasive aspergillosis has emerged as an important cause of morbidity and mortality in immunocompromised patients [1–5].”
• Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. (2004, background): “The overall mortality rate for IA remains dramatically high, approaching 90% in populations of the most profoundly immunocompromised patients [8, 9].”